This study compares the effectiveness and adverse event patterns of various ITP treatments. Eligible participants are those 18 years or older with a confirmed diagnosis of primary ITP with an initial platelet count less than 30,000/µl or with bleeding events. Participants with secondary ITP (such as low platelet counts caused by another autoimmune disease or infection); heart, kidney, or liver disease; or received NSAIDs within 1 month of trial initiation are ineligible for this study.
Upon diagnosis of primary ITP, all participants will be given high-dose dexamethasone. Afterwards, the participant will be randomly assigned to one of these groups: (1) continuation of high-dose dexamethasone, (2) prednisolone + azathioprine, (3) rituximab, (4) eltrombopag, or (5) romiplostim). Participants will be assessed weekly to adjust treatment doses. They will also be assessed at baseline, at end of treatment (6 months), and 6 months after treatment discontinuation for the following: increase in platelet count, bleeding, and adverse events.
Egypt
Actively Recruiting